Increasing geriatric population, susceptible to acute kidney injury (AKI), has created pressure on researchers and scientists to develop appropriate treatment and therapeutics. Currently, there are around 40 candidate drugs, meant for acute kidney injury treatment, and most of them are in their final stage of approval. The increasing patient pool is another factor that makes the acute kidney injury treatment market a highly lucrative proposition. Considering the evolutions in this landscape, and the possibilities of substantial opportunities, Transparency Market Research, in its new study, offers a 360 degree analysis on the key factors likely to influence market growth.

Evolution of Acute Kidney Injury (AKI) Treatment

Acute kidney injury, formerly known as acute renal failure, emerged as a prominent disease after the Second World War. Since then, more emphasis has been laid on the types of therapeutics that need to be developed that can effectively treat this ailment. Alkaline phosphatase, gemigliptin, and QPI002 are few therapeutics that are under clinical trial for treating AKI. As research on acute kidney injury gains momentum, new opportunities are likely to emerge. Influenced by a host of multi-pronged factors, the market for acute kidney injury treatment is likely to surpass a valuation of US$ 2.5 billion by the end of 2027.

Download Brochure Copy of Acute Kidney Injury Treatment Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=67523

The Therapeutic Landscape

Adoption of AKI Biomarkers

The adoption of advanced technologies plays a vital role in enhancing healthcare services. Currently, treatment provided for acute kidney injury is undergoing substantial changes, as researchers are using advanced new tools, predictive models, and biomarkers to improve dialysis procedures and stymie development of acute kidney injuries at an early stage. Emphasis is given on risk stratification along with AKI biomarkers that will enhance overall treatment.

Ultrasound Technique – A Traditional Break Through

Introduction of new ultrasound techniques is expected to provide better treatment for acute kidney injuries and chronic kidney diseases. As ultrasound technique is non-invasive, cost-effective, and offers simple imaging modality, it has opened new avenues for monitoring, diagnosis, and treating acute kidney injury. Ultrasound is capable of reducing the effect of AKI by encouraging the splenic cholinergic anti-inflammatory pathway. Further developments are also being made to enhance sensitivity and specificity of ultrasound that will result in providing precise results of diagnosing kidney disease.

Read Press Release of Acute Kidney Injury Treatment Market: https://www.transparencymarketresearch.com/pressrelease/acute-kidney-injury-treatment-market.htm

Market Players Collaborating with Research Institutes to Develop Effective Drugs

Researchers are engaged in studying different therapeutics that can be considered to treat AKI. Recently, researchers from the University of Alabama at Birmingham School of Medicine (UAB) and University of California San Diego School of Medicine received grants to enrich the skills especially for kidney diseases. The focus of the center is to evaluate kidney injury and function to improve diagnosis through several biomarkers. They also aim to identify targets for intervention and benefit in decision-making for physicians that will help in better management of patients with kidney diseases. Stakeholders in the acute kidney injury treatment market are keeping an eye on the results of these findings, as research and development remains a key success differentiator in this market. The go-to market strategies in this landscape are heavily influenced by the successful outcomes of research and development, and a substantial pie of the overall revenue share of stakeholders is spent on new product development. Therefore, industry-institution collaboration is likely to remain a norm rather than the exception in this market.

Vendors are making significant investments in research and development activities to develop drugs and treatment options for acute kidney injury. As mentioned earlier, as of now, there is no particular drug available in the market to treat AKI; therefore, research institutions and market participants are collaborating to develop drugs effective to treat acute kidney injury. At present, there are approx. 40 candidate drugs for AKI in different stages of development. Recently, Alloksys Life Sciences has developed therapeutic RESCAP®. This therapeutic drug is based on Alkaline Phosphatase (AP), a naturally available protein in the body. The aim of this therapeutic is to maintain Blood Brain Barrier (BBB), Kidney Glomerulus Barrier (KGB), Gut Barrier (GB), Lung Alveolar Barrier (LAB), and Placental Barrier (PB).

Expanding operations in future? To get the perfect launch ask for a custom report of Acute Kidney Injury Treatment Market

Moreover, LG Chem is also engaged in extensive research and development activities related to acute kidney injury treatment. LG Chem’sZemiglo is currently undergoing a clinical trial, and after gaining approval, it can be used to treat patients suffering from acute kidney injury. The development of these drugs will be beneficial for players, service providers, and patients. Market players will be capable of establishing themselves in a much profound manner, as most of drugs are in the final stage of approval. Hospitals and patients (end consumer) will also benefit largely from these developments. As the demand for specific drugs will be high in hospitals, and it can benefit both, the manufacturer and the hospital.

Mergers and Acquisitions: A Key Strategy

North America, led by the US, continues to be one of the leading markets for acute kidney injury treatment in the US. Leading companies are headquartered in this region, which makes it a prime location for research and development in this landscape. The presence of key players engaged in the development of novel drugs has meant that opportunities for manufacturers are high in the US and Canada as compared to markets where fewer companies are involved in research and development. The availability of new acute kidney injury products, such as QPI-1002 and Zemiglo along with innovative techniques are acting as a key contributor for market’s growth. Moreover, a large number of dialysis centers are present in the region (nearly 6,500 dialysis facilities in the United States alone, as per data by the National Kidney Foundation).

Mergers and acquisitions are another key strategy used by market players operating in the global acute kidney injury market. Recently, Fresenius Medical Care acquired 70% share of Chinese kidney hospitals and dialysis clinics – Guangzhou KangNiDaiSi Medical Investment Co., Ltd., mainly to expand its dialysis care network and to tap huge patient with kidney injury in this region. This acquisition will also trigger the development of dialysis centers with enhanced services in China. According to the Chinese Society of Nephrology, there are about 500,000 patients in China currently undergoing dialysis. This makes China the biggest market globally after the United States in terms of numbers.

Prevalence of acute kidney injury has grown substantially in Asia Pacific region–according to various studies, in South-East Asia, the AKI incidence was up to 18%~24% due to rising prevalence of malaria, leptospirosis, gastrointestinal tract infection, and monsoon climate. Moreover, in China the AKI incidence, misdiagnosis, and mortality rates were 1%-2%, 74.2%, and 12.4% respectively among hospitalized patients (2015). Thus, growing incidence of AKI has made government to develop supportive policies to treat acute kidney injury.

Governments in various countries are introducing supportive policies to spread awareness and provide better facilities to treat AKI. Higher prevalence of chronic kidney diseases (CKD) and growing interest in nephrology led to the initiation of The Kidney Disease Screening and Awareness Program (KDSAP) developed by Harvard College. A few years back, the Indian government started the National Dialysis Programme, under the National Health mission, an initiative of the Ministry of Health and Family Welfare. This initiative was carried out with the help of public-private partnerships at various hospitals. The aim was to provide life-saving procedure close by for patients, and to minimize the burden created by high medical costs.

Sirolimus could have a promising role in prophylaxis of rejection, treatment of refractory acute rejection, and chronic allograft dysfunction, as substantiated by various studies. Sirolimus is a new potent immunosuppressant whose profile could offer an advantage over other currently used drugs in view of its absence of intrinsic nephrotoxicity and efficacy as good as cyclosporin. Sirolimus could have both, a steroid sparing as well as a cyclosporin sparing effect.

Sirolimus may have a beneficial role in prophylaxis of rejection as well as treatment of refractory rejection. Sirolimus also has antifungal, antitumor, and anti-smooth muscle proliferative roles. The global sirolimus market was valued at US$ 285.00 Mn in 2018 and is projected to reach US$ 304.08 Mn by 2027, expanding at a CAGR of 1.0% from 2019 to 2027.

Promising Pipeline Opening New Market Opportunities

• Increase in incidence of target diseases, rise in the number of lifestyle-related disorders, promising pipeline, surge in health care spending, and improvement in health care infrastructure are the factors anticipated to drive the global sirolimus market.
• Furthermore, increase in preference for generic drug variants and associated side effects are expected to restrain the Sirolimus market.

Download Brochure Copy of Sirolimus Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=66860

Global Sirolimus Market: Report Segmentation

• In terms of application, the global sirolimus market has been categorized into organ transplant rejection, lymphangioleiomyomatosis (LAM), and sirolimus coated balloons & catheter devices.?

• The organ transplant rejection segment dominated the sirolimus market in 2018 due to rise in the number of organ transplants.
• Based on distribution channel, the global sirolimus market has been classified into hospital pharmacies, retail pharmacies, and online pharmacies.
• In terms of region, the global sirolimus market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
• 
  North America accounted for major share of the global sirolimus market in 2018. The market in the region is driven by the presence of key players and high rate of adoption of technologies.
  Additionally, rise in the number of organ transplants is projected to propel the market in North America.
  Increase in incidence of target diseases, rise in prevalence of lifestyle-related disorders, promising pipeline, and surge in health care spending & improvement in health care infrastructure is anticipated to boost market growth.
  
  

Read Press Release of Sirolimus Market: https://www.transparencymarketresearch.com/pressrelease/sirolimus-market.htm

Global Sirolimus Market: Competitive Insights

The global sirolimus market is highly fragmented due to the presence of a large number of players. Major players operating in the market include Pfizer, Inc., Biocon, Dr. Reddy’s Laboratories Ltd., Concept Medical, Inc., Stentys SA, Torrent Pharmaceuticals Ltd., Zydus Cadila, and Intas Pharmaceuticals Ltd.

Increase in trend of mergers & acquisitions and product approvals & launches in developing countries is expected to boost the global sirolimus market during the forecast period. Additionally, acquisitions drive growth in core business. Product approvals enable companies to enhance product portfolio globally.

The global sirolimus market has been segmented as follows:

• 
  Global Sirolimus Market, by Application
  Organ Transplant Rejection
  Lymphangioleiomyomatosis (LAM)
  Sirolimus Coated Balloons & Catheter Devices
  
  
• 
  Global Sirolimus Market, by Distribution Channel
  Hospital Pharmacies
  Retail Pharmacies
  Online Pharmacies
  
  

Request a PDF Sample – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=60162

High Prevalence of Urinary Incontinence and Overactive Bladder to Propel Market

Urinary incontinence is one of the highly prevalent and largely underreported and underdiagnosed urological disorders across the globe. It affects millions of people and has severe impact on physical, psychological, as well as emotional health. Twice as many women as men are affected by this condition and its incidence increases with age. Several factors such as weak pelvic floor muscles, urethral sphincters, obesity, pregnancy & childbirth, urinary tract infection, and neurological disorders cause urinary incontinence. An estimated 200 million people globally are affected by some form of urinary incontinence or bladder problems. Stress urinary incontinence is the most common form affecting millions of people. Various studies have suggested that 24% to 45% of women aged above 30 suffer from stress urinary incontinence. Large patient pool with stress urinary incontinence and overactive bladder symptoms is projected to fuel the growth of the global urinary incontinence treatment devices during the forecast period.

Download Brochure Copy of this Report: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=60162

Electrical Stimulation Devices to be Most Attractive Segment

The report offers detailed segmentation of the global urinary incontinence treatment devices market based on product, incontinence type, and end-user. In terms of product, the electrical stimulation devices segment is poised to account for leading share of the global market during the forecast period. Factors attributed to the higher share of the segment include rise in demand for minimally invasive/wearable and non-implantable electrical stimulation devices to strengthen the pelvic floor muscles, high success rates with electrical stimulation devices, and favorable medical reimbursement policies in developed countries for implantable electrical stimulation devices. Development and launch of new electrical stimulation devices for percutaneous tibial nerve stimulation for the treatment of overactive bladder (such as Medtronic plc’s NURO System) is projected to drive the segment during the forecast period. Moreover, recent launch of wearable electrical stimulation device, INNOVO, by Atlantic Therapeutics and rise in demand for InControl Medical’s FDA-approved over-the-counter electrical stimulation device are expected to propel the segment during the forecast period.

Urge Urinary Incontinence Segment to Dominate Market

In terms of incontinence type, the urge urinary incontinence segment is projected to dominate the global urinary incontinence treatment market during the forecast period. The segment is anticipated to expand at a high CAGR from 2019 to 2027. Millions of people across the globe are affected by overactive bladder which leads to urge urinary incontinence. Dominance of the segment is attributed to higher cost of treatment devices, especially implantable electrical stimulation devices, than other treatment devices/methods. Therefore, increase in incidence of urge urinary incontinence, rise in adoption of electrical stimulation devices for overactive bladder treatment, and new product launches are expected to contribute to the growth of the segment during the forecast period.

Hospitals Segment to Lead Market

Based on end-user, the hospitals segment is projected to account for major share of the global urinary incontinence treatment devices market from 2019 to 2027. The segment is anticipated to expand at a high CAGR from 2019 to 2027. Ambulatory surgery centers is expected to be the second leading segment in terms of market share during the forecast period. High share of the segment is attributed to increase in the number of surgical procedures for the treatment of all types of urinary incontinence and favorable reimbursement policies for medical devices in most of the developed and developing countries. The home use segment is likely to grow at a rapid pace from 2019 to 2027. Availability and high adoption of over-the-counter electrical stimulation and non-invasive treatment devices for the effective management of urinary incontinence are the key factors driving the home use segment.

Europe to Create High Incremental Opportunity

In terms of revenue, North America is projected to dominate the global urinary incontinence treatment devices market from 2019 to 2027. This is attributed to early adoption of technologies, large patient pool of urinary incontinence, and easy availability & lucrative medical reimbursement policies in the U.S. and Canada. Europe is anticipated to be the second largest and most attractive market for urinary incontinence treatment devices. The market in the region is expected to expand at a high CAGR during the forecast period due to high prevalence and increase in incidence of urinary incontinence, surge in adoption of technologically advanced products, large base of medical devices companies, and large number of products in the pipeline for the treatment of urinary incontinence. The market in the U.K. is likely to expand at the highest CAGR during the forecast period. The country is projected to gain market share from 2019 to 2027. An estimated 15,000 mid-urethral sling surgical procedures (MUS) in women are performed in the U.K. each year. Moreover, high incidence of post radical prostatectomy urinary incontinence in men is anticipated to accelerate the growth of the market in the country during the forecast period. Asia Pacific is expected to be the second fastest growing market for urinary incontinence treatment devices owing to large population in countries such as India and China, large geriatric population in Japan, and improving health care facilities.

New Product Development and Launch in International Market: Key Trend among Leading Players

The report also provides profiles of leading players operating in the global urinary incontinence treatment devices market. Boston Scientific Corporation, C. R. Bard, Inc. (Becton, Dickinson and Company), Coloplast Group, Promedon Group, Medtronic plc, and Ethicon US, LLC. (Johnson & Johnson) are the major players operating in the market offering products with proprietary technologies. Several companies have introduced mini slings for minimally invasive placement of mid-urethral slings with polypropylene sling material. In March 2016, Medtronic plc launched the NURO System, a percutaneous tibial neuromodulation device for the treatment of overactive bladder. The NURO System is the second product in the market after Cogentix Medical’s Urgent PC that targets tibial nerve for pelvic floor strengthening. Other prominent players in the global urinary incontinence treatment devices market include ZSI Surgical Implants S.R.L., InControl Medical LLC, Hollister Incorporated, Atlantic Therapeutics Group Ltd., B. Braun Melsungen AG, A.M.I. GmbH, and Teleflex Incorporated

Chromoendoscopy is an adjunctive endoscopy technique that involves spraying of dyes on the gastrointestinal mucosal surface to identify specific epithelia or to enhance mucosal surface characteristics of the gastrointestinal epithelium. It is performed to aid in the detection of subtle lesions or to allow directed targeting of biopsies to increase the yield of endoscopic diagnostic accuracy.

The global chromoendoscopy agents market was valued at US$ 108.9 Mn in 2017 and is anticipated to reach US$ 146.5 Mn by 2026, expanding at a CAGR of 3.4% from 2018 to 2026. Rise in prevalence of gastrointestinal diseases, technological advancements in imaging techniques, surge in awareness among people about preventive measures of cancer, and increase in the number of endoscopy procedures are factors projected to propel the global market during the forecast period.

The global population is ageing rapidly. According to the WHO, nearly 2 billion people are expected to be aged 60 and above by 2050, which is around 16.7% of the global population. The population in developed countries such as those in Western Europe, Japan, and the U.S. is ageing at a high rate. Some reasons behind it are better health care infrastructure & polices and adoption of advanced medical techniques. Additionally, access to various diagnostic and treatment services has improved in these countries in the past few years. This, in turn, has increased the life expectancy of the overall population. Treatment procedures such as colonoscopy, lung surgeries, hip & knee implants, gastrointestinal endoscopic procedures, and bariatric surgeries are common among the geriatric population. A rise in the geriatric population leads to high rates of ailments. These factors are likely to drive demand for and adoption of endoscopic devices and agents.

Download Brochure Copy of Chromoendoscopy Agents Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=37196

The global chromoendoscopy agents market has been segmented based on product type, application, end-user, and region. In terms of product type, the absorptive agents segment is projected to account for major share of the market. Absorptive agents improve the recognition of minute changes in the surface pattern by enhancing the contrast of raised and deepened area. This facilitates the visualization and detection of dysplastic and malignant lesions in the gastrointestinal tract. Based on application, the colorectal cancer segment held major share of the market in 2017. The segment is anticipated to expand at a higher CAGR than the other segments during the forecast period. Chromoendoscopy agents have proven to be effective in the detection and visualization of colon neoplasia.

Read Press Release of Chromoendoscopy Agents Market: https://www.transparencymarketresearch.com/pressrelease/chromoendoscopy-agents-market.htm

In terms of region, the global chromoendoscopy agents market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. Developed regions such as North America and Europe accounted for leading shares of the global market in 2017. Large patient population and presence of major medical devices companies in these regions can be attributed to high share of these regions. Moreover, rise in prevalence of gastrointestinal diseases and increase in the geriatric population drive the chromoendoscopy agents market in these regions. The market in Asia Pacific is projected to expand at a high CAGR owing to rapidly improving health care facilities in countries such as India, China, South Korea, and Malaysia. China dominated the chromoendoscopy agents market in Asia Pacific in 2017. The market in India is anticipated to expand at a significant CAGR during the forecast period. Furthermore, increase in investment by leading market players and health care providers is expected to fuel the growth of the market in the region. These factors are likely to drive demand for chromoendoscopy agents in the near future. The market in Latin America and Middle East & Africa is projected to expand at a steady pace during the forecast period.

Prominent players operating in the global chromoendoscopy agents market include Cosmo Pharmaceuticals NV, Provepharm Life Solutions, Enzo Life Sciences, Inc., Sisco Research Laboratories Pvt. Ltd., HISTALIM, Merck KGaA, Thermo Fisher Scientific, Inc., and LobaChemie Pvt. Ltd.

Vascular grafts are used to redirect blood flow from one part of the body to another by connecting blood vessels. Vascular grafting surgery is performed to treat ischemia caused by atherosclerosis, organ transplantation, or for vascular access in hemodialysis. However, demand for vascular grafts is anticipated to decline during the forecast period owing to increase in adverse effects like decellularized xenogeneic grafts increase the rate of infection, thrombosis, and aneurysms.

The global vascular grafts market was valued at US$ 2,010.1 Mn in 2017 and is projected to expand at a CAGR of 5.0% from 2018 to 2026 to reach US$ 3,000 Mn by 2026. High incidence rate of cardiovascular diseases, peripheral diseases, and rise in geriatric population are likely to fuel the growth of the global market from 2018 to 2026. Surge in government investment in health care infrastructure and strategic alliances among players to penetrate the emerging markets are expected to propel the global market during the forecast period.

In terms of product, the global vascular grafts market has been segmented into endovascular stent grafts, peripheral vascular grafts, hemodialysis access grafts, bypass grafts, and others. The endovascular stent grafts segment held the largest market share in 2017. Moreover, the segment is anticipated to expand at a high CAGR during the forecast period due to high demand for minimally invasive surgeries and rise in preference for stent grafts to treat atherosclerosis. Based on source, the global market has been classified into synthetic, biological, and biosynthetic.

Download Brochure Copy of Vascular Grafts Market : https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=62916

The synthetic segment is projected to dominate the global market during the forecast period owing to its good materialistic properties such as flexibility. In terms of size of vascular graft, the global vascular graft market has been bifurcated into large and small. The small segment is expected to expand at a high CAGR due to increase in focus of major players on the development of small size vascular grafts to treat narrow vascular atherosclerosis. Based on end-user, the global market has been divided into hospitals, ambulatory surgery centers, cardiac catheterization laboratories, specialty clinics, and others. The hospitals segment accounted for the largest market share in 2017. The segment is expected to expand at a significant CAGR during the forecast period.

North America is projected to account for major share of the global vascular grafts market from 2018 to 2026, supported by rise in prevalence of cardiovascular diseases and increase in the number of vascular surgeries. According to the Journal of Vascular Surgery (2012), critical limb ischemia is associated with significant cost to the U.S. health care system and is estimated to exceed US$ 3 Bn annually. According to data provided by the American College of Cardiology, more than 130 million adults in the U.S. are anticipated to have some form of cardiovascular diseases (CVD) by 2035, and the total cost of CVD is expected to reach US$ 1.1 Trn in 2035. The vascular graft market in Asia Pacific is likely to expand at a high CAGR during the forecast period due to increase in focus on development of health care infrastructure by both public and private hospitals and high cardiovascular patient pool in countries such as India and China.

Read Press Release of Vascular Grafts Market : https://www.transparencymarketresearch.com/pressrelease/vascular-grafts-market.htm

Key companies operating in the global vascular grafts market and profiled in the report include W. L. Gore & Associates, Inc., Maquet Holding B.V. & Co. KG (Getinge Group), BD, LeMaitre Vascular, Inc., B. Braun Melsungen AG, Cook Medical, Medtronic plc, Artegraft, Inc., Vascutek Ltd., Vascular Graft Solution Ltd., Heat Medical Europe BV, and CryoLife, Inc.

Anticoagulants prevent clot formation or enlargement of existing clots in the arteries or veins. Heparins, including unfractionated heparin (UFH) and low molecular weight heparin (LMWH); vitamin K antagonists, DTIs, and factor Xa inhibitors, are the various anticoagulants available in the market. These are used for indications such as heart attack, stroke, deep venous thrombosis (DVT), pulmonary embolism (PE), surgery, angina, dialysis, atrial fibrillation (AF), thrombocytopenia, and myocardial infarction.

Request a PDF Sample of Anticoagulants Market – https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=60924

Increase in Geriatric Population

Dwindling birth rates have led to an increase in the geriatric population. In Japan, people aged 65 and above currently constitute 23% to 25% of the total population. The percentage is projected to reach 38% by 2050. In North America, the estimates are between 13% and 22% and between 16% and 27% in Europe. Rise in standard of health care facilities and availability of advanced treatment options boost life expectancy rates across the world. This in turn increases the geriatric population. According to the UN Population Division, the number of people aged 60 and above is anticipated to increase significantly during 2015–2030. In developed countries, the percentage of people aged 60 and above has increased from 12% in 1950 to 22% in 2011 and is expected to reach 32% by 2050. On the other hand, in developing countries, the percentage of people aged 60 and above increased from 6% in 1950 to 9% in 2011 and is likely to reach 20% by 2050. Aging makes people prone to fractures and injuries, as their bone density decreases, making them fragile and increasing their susceptibility to falls and arthritis-related fractures. Cardiovascular diseases, kidney disease, osteoporosis, rheumatoid arthritis, and osteoarthritis are common age-related disorders. People aged above 60 are more prone to diseases and disorders. These factors drive demand for anticoagulants products among the geriatric population.

Request Brochure of Anticoagulants Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=60924

Rise in Cases of Coagulation Disorders

The rise in adoption of Novel Oral Anticoagulants (NOACs) boosts market growth. NOACs target either factor Xa to avoid or to treat thrombosis. These show rapid action and do not require constant monitoring. NOACs also have better efficacy and safety profiles than conventional therapies such as warfarin. Therefore, adoption rate of NOACs has increased in the global anticoagulant market.

Since the introduction of anticoagulants antidotes such as idarucizumab in the market in 2015, acceptance of NOACs has increased, as these eliminate the risk of bleeding. Xarleto and Eliquis are two anticoagulants increasingly preferred by physicians. Xarleto reported a Y-o-Y growth of nearly 10% in 2015, due to increase in volume in some of the key countries such as Japan and Germany. Sales of Eliquis rose by 140.3% due to increase in demand for NOACs globally.

Rise in Prevalence of Obesity

Obesity is a key factor for the rise in the number of people suffering from kidney disorders, cardiovascular disorders, and stroke. This is also attributed to changes in lifestyle and lack of physical activity. According to CDC 2015 report, nearly 950,000 people are affected by pulmonary embolism (PE) or deep vein thrombosis (DVT). Moreover, these conditions account for 65,000 to 100,000 deaths in the U.S. each year. Additionally, more than 10% of the geriatric population of the U.S., which accounts for 25 million people, is affected by kidney diseases associated with thrombosis. This is because aging increases the risk of developing renal and cardiovascular diseases, with chances of thromboembolic and hemorrhagic events also rising. This condition is treated using anticoagulants. Increase in the number of people suffering from DVT and surge in number of surgeries are expected to drive the global anticoagulants market.

Increase in Hip and Knee Surgeries

Rise in the number of knee and hip replacement surgeries increases the risk of DVT. For example, surgeries often result in long period of immobility, which increases the chances of developing DVT due to less blood flow in the body. According to CDC 2016 report, over a million people in the U.S. undergo hip and knee replacement surgeries each year. Moreover, the number of surgical procedures has increased among the geriatric population across the globe. Rise in the number of surgeries increases the risk of developing thromboembolic events. This drives demand for treatment using anticoagulants among patients.

North America to Dominate Global Market

Rise in surgical procedures such as hip and knee replacements is projected to increase the patient pool for treatment with anticoagulants in North America and Europe. According to the Centers for Disease Care and Prevention (2015), around 719,000 knee replacement and 332,000 hip replacement surgeries were performed in the U.S. in 2014. Asia Pacific is expected to be the most lucrative market for anticoagulants from 2018 to 2026. Increase in disposable income, rise in population, and expansion of key players in the region are likely to boost the growth of the anticoagulants market in Asia Pacific.

Cardiac arrest is defined as a sudden and abrupt loss of heart function, consciousness, and apnea or agonal breathing. It is a heterogeneous condition in terms of underlying pathology. It results from an electrical disturbance in the heart because of a problem with electrical signals. The disturbance leads to disruption in pumping action and stoppage of blood flow to the body. Cardiac arrest is often fatal. If appropriate steps are not taken immediately, sudden cardiac arrest can lead to death. The most common cause of a cardiac arrest is abnormal heart rhythm such as ventricular tachycardia or ventricular fibrillation. Other causes of cardiac arrest include thickened heart muscles (cardiomyopathy), heart medications, electrical abnormalities, blood vessel abnormalities, recreational drug use, and scarring of the heart tissue.

Obesity, diabetes mellitus, smoking, high cholesterol, high blood pressure, and sedentary lifestyles are the primary causes of heart failure and cardiac arrest. Rise in the number of people afflicted by these diseases is projected to drive demand for cardiac arrest treatment. According to the American Heart Association’s 2017 Heart Diseases and Stroke Statistics update, the number of people diagnosed with heart failure is increasing and projected to rise by 46% by 2030, resulting in more than 8 million people with heart failure. There are 22 million people living with congestive heart failure across the world and additional 2 million people are diagnosed every year. According to the American Heart Association, congestive heart failure is one of the leading causes of death in the U.S., accounting for 8.5% of the total population. According to the World Journal of Cardiovascular Diseases, more than 7 million deaths occur due to sudden cardiac arrest across the globe each year. Sudden cardiac death accounts for about 20% of all mortalities in the West. According to the U.S.

Download Brochure Copy of Cardiac Arrest Treatment Market : https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=61416

National Library of Medicine of the National Institutes of Health, 40% to 50% of all cardiovascular deaths are sudden cardiac deaths (SCDs) and nearly 80% of these are caused by ventricular tachyarrhythmia. Therefore, about 6 million sudden cardiac deaths occur each year due to ventricular tachyarrhythmia. The overall prevalence of first degree atrioventricular block among the adult population in the U.S. is 3.7%. Prevalence of atrioventricular block is higher in patients with coronary heart diseases. Dual CRT pacemakers are implanted due to symptomatic bradycardia, which is caused by sick sinus syndrome or atrioventricular block or both. Untreated atrioventricular block will not only lead to heart failure, but also sudden cardiac death. However, stringent regulations for medical devices required for the treatment of cardiac arrest are expected to restrain the market during the forecast period.

The global cardiac arrest treatment market has been segmented based on treatment, sales channel, and region. In terms of treatment, the medical devices segment held major market share in 2018 and the trend is projected to continue during the forecast period. The beta blockers sub-segment is anticipated to dominate the drugs segment from 2019 to 2027. In terms of sales channel, the hospitals segment is likely to lead the global cardiac arrest treatment market during the forecast period.

Read Press Release of Cardiac Arrest Treatment Market : https://www.transparencymarketresearch.com/pressrelease/cardiac-arrest-therapeutics-market.htm

Geographically, North America dominated the global cardiac arrest treatment market in 2018, accounting for the largest share. The region was the largest market for cardiac arrest treatment due to high adoption rate of CRT for cardiac arrest treatment among cardiologists and heart specialists and presence of large number of AED centers. Moreover, increase in incidence of cardiovascular disorders and advancements in medical devices for the treatment of cardiac arrest drive the cardiac arrest treatment market in North America. The market in Asia Pacific is expected to expand at a high CAGR from 2019 to 2027. Asia Pacific comprises major economies such as China, Japan, India, Australia, South Korea, and New Zealand. The cardiac arrest treatment market in Asia Pacific is growing rapidly compared to Europe and North America, which have shown stagnant growth in the past few years. Factors contributing to strong market growth in Asia Pacific are increase in incidence of sudden cardiac arrest (SCA), large patient base, rise in purchase of AEDs for organizational and corporate defibrillation programs, over-the-counter availability of AEDs, increase in disposable income, and subsequent spending on health care.

Key players operating in the global cardiac arrest treatment market include Amgen, Inc., Pfizer, Inc., Johnson & Johnson, Novartis AG, Bristol-Myers Squibb Company, Abbott, Bayer AG, Koninklijke Philips N.V., GE Healthcare, Physio-Control, Inc. (Stryker), Boston Scientific Corporation, Cardiac Science Corporation (Aurora Capital Group), and Shenzhen Mindray Bio-Medical Electronics Co., Ltd.

Worldwide increase in the prevalence of gynecological disorders

Gynecologic disorders affect the female reproductive system. The most common symptoms of gynecologic disorders include pelvic pain, vaginal itching, vaginal discharge, abnormal vaginal bleeding, and breast pain and lumps. The significance and severity of these symptoms often depend on age, as these symptoms may be related to hormonal changes that occur with aging.

Request a PDF Sample of Gynecology Drugs Market: Gynecology Drugs Market :https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=54756

Among other prominent gynecological diseases, sexually transmitted disease (STD) is the most common and critical – the most common STD among women is pelvic inflammatory disease. In the U.S. alone, more than one million women suffer from this disorder in their lifetime, followed by chlamydia – a sexually transmitted infection of the vagina, which, if left untreated, develops into pelvic inflammatory disease. Gynecological disorders may or may not be related to the menstrual cycle, which prominently include menstrual cramps and endometriosis (abnormally located patches of tissue that is normally located only in the lining of the uterus). Additionally, gynecological cancers are also common among women around the globe. Endometrial cancer and ovarian cancer are highly common among women. Therefore, increase in the prevalence of the conditions mentioned above, are likely to increase the uptake of gynecology drugs.

Rise in number of women facing menopausal conditions

Rise in number of women facing menopausal condition is a major factor that is expected to drive the market during the forecast period. Menopause is defined as permanent cessation of menstruation, resulting from loss of activity of ovarian follicles. In a majority of women, menopause is a natural event occurring at the age of around 51.3 years. The number of women entering menopausal condition is increasing year on year, due to unhealthy lifestyle and different environmental factors. In Canada, presently, over five million women aged between 45 and 65 have either gone through menopause or are expected to soon go through menopause. The average age of menopause in Canada is 51 years. Moreover, according to the Society of Obstetricians & Gynecologists of Canada, around 80% women claim to suffer from at least one menopausal symptom including mood swings, irritability, interrupted sleep, hot flashes, and vaginal dryness. Incidence of menopausal vasomotor symptoms has risen significantly in the last few years, which in turn drives the global gynecology drugs market.

Request Brochure of Gynecology Drugs Market : https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=54756

The global gynecology drugs market has been segmented based on therapeutics, indication, distribution channel, and region. Furthermore, in terms of therapeutics, the market has been divided into hormonal therapy and non-hormonal therapy. The non-hormonal therapy segment is likely to account for a leading share of the global market during the forecast period owing to the effectiveness of the products, rising adoption of these products, and new product development. Decreasing use of hormonal products due to the risk of breast cancer has boosted the demand for non-hormonal pharmaceutical products. In terms of indication, the market has been classified into gynecology cancers, endometriosis, female infertility, menopausal disorder, gynecology infections, polycystic ovary syndrome, contraception (birth control), and others. In terms of distribution channel, the market has been segregated into hospital pharmacies, retail pharmacies, and online pharmacies. The online pharmacies segment is projected to expand at a significant CAGR during the forecast period, owing to the ease of using online pharmacy and rise in the number of internet users.

Huge patient base of gynecology disease in Asia Pacific to create opportunities in market

In terms of region, the global gynecology devices market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America is projected to hold a leading share of the global market during the forecast period, owing to high rate of adoption of technological advanced products, presence of key players, and high health care expenditure. Europe is anticipated to account for a significant share of the global market between 2018 and 2026. Increase in incidence of gynecological diseases is expected to fuel the market in the region during the forecast period. The market in Asia Pacific is likely to witness robust expansion during the forecast period, due to surge in health care expenditure. Moreover, increasing focus of key players on expansion in Asia Pacific, large untapped population in the region, and rising awareness about health care drive the gynecology drugs market in Asia Pacific. The gynecology drugs market in Latin America and Middle East & Africa is anticipated to expand at a steady pace from 2018 to 2026.

Key players profiled in this report are Eli Lilly and Company, Pfizer, Inc., Merck & Co., Inc., Sanofi, Amgen Inc., Lupin Pharmaceuticals, Inc., AstraZeneca, F. Hoffmann-La Roche Ltd., Allergan Plc, GlaxoSmithKline plc, Bayer AG, and Johnson & Johnson. Companies operating in the global gynecology drugs market focus on strategic collaborations to develop new products in emerging markets such as Asia Pacific and Latin America.

Increase in Use of Illicit drugs to Propel Market

Abuse of prescription drugs or nonmedical use of prescription drugs has become a serious public health issue owing to its high prevalence and mortality rates in the U.S. Illicit use of prescription drugs has increased in the past few years which has resulted in rise in number of deaths caused due to drug overdose. According to the National Survey on Drug Use and Health in 2015, lifetime rates for illicit drugs use varied among different age groups. The rate was more than 50% for persons aged 19 to 59 years, 53.8% for persons aged 60 to 64 years, and only 25.8% for older population aged 65 and above. This increase in use of illicit drugs is anticipated to drive demand for drugs of abuse testing during the forecast period.

Request a PDF Sample of Drugs Of Abuse Testing Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=54426

Rise in Demand for Drugs of Abuse Testing among Private Employers

Drug abuse is a serious health issue posing significant impact on the health, business, and society as a whole. Individuals using illicit drugs at workplace affect the productivity and competitiveness of the business sector. Several private employers are now conducting drug abuse testing regularly for their employees to curb economic burden of costs, lost work productivity, and health care caused due to drug abuse. Increase in demand for drug abuse testing services among private employers is expected to drive the market during the forecast period. According to the National Institute of Drug Abuse, alcohol, tobacco, and illicit drugs create an economic burden of nearly US$ 740 Bn in the U.S. through related costs, lost work productivity, and health care.

Low Awareness about Drugs of Abuse Testing in Developing and Underdeveloped Countries to Restrain Market

The drugs of abuse testing market is anticipated to witness sluggish growth during the forecast period in developing and underdeveloped countries in Asia Pacific, Latin America, and Africa. This is attributed to low awareness about drugs of abuse testing services coupled with inadequate social support and lack of stringent regulation which make drug abuse testing mandatory. According to a report published by the World Health Organization, nearly 77% of children in Brazil are reported to consume alcohol regularly.

Request Brochure of Drugs Of Abuse Testing Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=54426

North America Market to Witness Strong Growth

North America accounted for the largest share of the global drugs of abuse testing market in 2017. Rise in drug consumption, increase in awareness about harmful effects of drugs, and surge in workplace screening are factors boosting market growth in the region. The consumables segment in North America accounted for the largest market share in 2017. Usage of reagents and consumables such as gloves and sample collection devices is increasing in the region. This in turn is expected to propel demand for drugs of abuse testing consumables in North America. An estimated US$ 600 Bn is spent on addressing the impact of substance abuse in the U.S. each year. According to the Substance Abuse and Mental Health Services Administration (SAMHSA), nearly 22.5 million individuals aged 12 and above were reported to seek treatment for alcohol and illicit drug use in the U.S. in 2014.

Alere, Inc. and F. Hoffman-La Roche Ltd. to Lead Market

The global drugs of abuse testing market has several players offering various products for screening of illicit drugs and alcohol consumption. Alere, Inc. is anticipated to dominate the global market during the forecast period, followed by F. Hoffman-La Roche Ltd. Technological advancements, rise in awareness about the availability of drug abuse testing solutions, and adoption of expansion strategy by major manufacturers to increase global reach are anticipated to propel the global market during the forecast period. For instance, Siemens Healthineers provides education through Syva Drug Testing Online Campus for customers to keep them abreast of important information and emerging trends in drug testing.

Ever since the era of biotechnology began, with the development of recombinant DNA (rDNA) techniques, countless experiments and research regarding the implication of biotechnology to boost health continue to spawn. The advancement of biotechnology has opened new doors to designing novel therapeutic drugs for sophisticatedly fighting diseases.

Rapid advancements in stem cell research emphasize using a patient’s own cells to design highly personalized therapeutic alternatives. Similarly, genetic engineering technology encompasses editing the genetic composition of patients to encounter specific points of interest. Several measures are being taken to explore and incorporate biotechnology into the creation of personalized medical care. The application of biotechnology towards personalized medical treatments is likely to open several opportunities for red biotechnology market competitors. Although red biotechnology sustains on an upward growth trajectory in wake of its consist contribution in bettering healthcare, it is imperiled to potential setbacks that cannot be denied. The influence of regional governance on the pricing of medication brings along an undermining aspect, as growing innovations need to be remunerated.

The new study by TMR reveals key insights into the red biotechnology landscape, allowing report audiences to gain a holistic market overview. According to this TMR study, sales revenues from the red biotechnology market valued at US$ 314.2 billion in 2018. The increasing prevalence of chronic diseases, rapid expansion of the biopharmaceutical industry, and increased global expenditure on the healthcare industry are likely to uphold the growth of the red biotechnology market. Moreover, the growing awareness of chronic disease treatment and robust pipeline of new therapeutic molecules are expected to drive the global red biotechnology market.

Download Brochure Copy of Red Biotechnology Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2063

Notable Trends Shaping the Future of the Red Biotechnology Market

AI Ushers in the New Era of Biotechnology Research

The transforming utilization of artificial intelligence across a wide array of applications has not been unnoticed. Ahead of this, its use has gradually commenced revolutionizing research activities in the field of biotechnology, as it dramatically minimizes the cost and time involved in the development of life-saving drugs. Companies within the biotechnology space have gained a competitive edge with the implications of cloud-based technology and AI, and increased focus on R&D.

Significant Investments in the Healthcare Space

There is a continuously growing buoyancy for supporting industries in the biotech sector, including health service companies. Healthcare start-ups are shining brightly for investors, particularly in areas such as biotechnology. The healthcare industry, as a whole, has cited that dollars of investments and higher valuations are likely to stay consistent over the foreseeable future, giving an edge to research activities for biopharmaceutical production.

Strategic Collaborations Lay the Grounds for Success

Red biotechnology market players are relying on strategic mergers and acquisitions to strengthen their position in the market. As enhanced therapeutics play a major role in global disease mitigation, red biotechnology market players are emphasizing on strategic collaborations to enhance their level of expertise while bringing in innovative products. With collaboration agreements, red biotechnology market players are likely to gain major support for biopharmaceutical production, which is picking pace rapidly.

Read Press Release of Red Biotechnology Market: https://www.transparencymarketresearch.com/pressrelease/red-biotechnology-market.htm

Growing Demand for Therapeutics to Stir New Possibilities

The growing rate of chronic diseases is compelling researchers to develop advanced drugs and therapeutics that are capable of battling chronic and progressive diseases. On account of continuous developments in therapeutics for an array of diseases, and perpetual efforts towards effective R&D for drug development, product approvals by international regulatory bodies are gaining significant traction, thereby boosting developments in the red biotechnology market.

Key Success Strategies for Red Biotechnology Competitors

Strengthen Partnership and Distribution Agreements in Developing Countries

Global red biotechnology market players are emphasizing on developing countries, particularly in the Asia Pacific region. With major initiatives taken in response to the growing drug and biologics demand, and growing patient population in this region, global market players concentrate on strengthening distribution and partnership agreements in developing countries to leverage major demand for biopharmaceuticals and biosimilars.

Looking for exclusive market insights from business experts? Request a Custom Report of Red Biotechnology Market

Expand Global Oncology Portfolio

Growing incidences of cancer across the globe have spawn major developments in cancer therapeutics, resulting in increasing investments in cancer research and drug development. Red biotechnology market competitors have recognized the importance of cancer therapeutics, directing major focus towards oncology portfolio expansion.

Greater Investment in R&D to Develop Novel Biopharmaceuticals

Biopharmaceuticals production continues to be the most sought-after application of red biotechnology on account of the fast-growing demand for these drugs that target disease pathways, and provide superior efficacy and safety. Their ability to treat previously untreatable diseases have made biologics widely accepted among end users, driving the demand for hefty investment in biopharmaceutical R&D.

Boost Market Presence in the U.S.

There is a major concentration of entrepreneurialism and research in U.S. biotechnology companies, with a biotechnology cluster based in the country. Higher rate of acceptance of new biopharmaceutical drugs, coupled with massive product launches in North America, is attributed to the dominance of the region, wherein, the U.S. is likely to thrive as a leader in the biotechnology space. A large number of mature biotechnology companies and pharmaceutical manufacturers located in the U.S. are attracting red biotechnology market contributors in a bid to expand their presence in the country.

Innovative Product Development and Clinical Trials

Companies operating in the red biotechnology market continue to engage in the development of innovative products and invest in associated clinical trials to gain regulatory backing. As R&D efforts for producing advanced disease therapeutics continues to flourish, red biotechnology innovations remain a vital profit-gaining strategy for competitors.

Competitive Assessment

Leading players in global red biotechnology market, including

• F. Hoffmann-La Roche
• Amgen Inc.
• Gilead Sciences Inc.
• CSL
• Pfizer Inc.

accounted for nearly half of the market share in 2018. Expansion strategies such as business acquisitions remain a vital tactic adopted by competitors in the red biotechnology market. Companies are entering into strategic collaborations with other biotechnology firms located in lucrative geographies, in a bid to expand their consumer base. Apart from this, innovative product launches allow red biotechnology market players to strengthen their market position, with focus centered on greater R&D activities. Considering the global inclination towards biosimilars that meet the consumer requirements for both, efficacy and cost-effectiveness, notable developments related to biosimilars remain a focal point for competitors.